- Home
- CPHC vs MGNX Comparison
CPHC vs MGNX Comparison
Compare CPHC & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPHC
- MGNX
- Stock Information
- Founded
- CPHC 1994
- MGNX 2000
- Country
- CPHC United States
- MGNX United States
- Employees
- CPHC N/A
- MGNX N/A
- Industry
- CPHC Services-Misc. Amusement & Recreation
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- CPHC Consumer Discretionary
- MGNX Health Care
- Exchange
- CPHC Nasdaq
- MGNX Nasdaq
- Market Cap
- CPHC 92.5M
- MGNX 99.7M
- IPO Year
- CPHC 1994
- MGNX 2013
- Fundamental
- Price
- CPHC $16.94
- MGNX $1.65
- Analyst Decision
- CPHC
- MGNX Hold
- Analyst Count
- CPHC 0
- MGNX 6
- Target Price
- CPHC N/A
- MGNX $3.20
- AVG Volume (30 Days)
- CPHC 2.1K
- MGNX 576.8K
- Earning Date
- CPHC 11-06-2025
- MGNX 11-04-2025
- Dividend Yield
- CPHC 1.66%
- MGNX N/A
- EPS Growth
- CPHC N/A
- MGNX N/A
- EPS
- CPHC 0.03
- MGNX N/A
- Revenue
- CPHC $60,069,270.00
- MGNX $165,495,000.00
- Revenue This Year
- CPHC N/A
- MGNX N/A
- Revenue Next Year
- CPHC N/A
- MGNX N/A
- P/E Ratio
- CPHC $558.56
- MGNX N/A
- Revenue Growth
- CPHC N/A
- MGNX 303.47
- 52 Week Low
- CPHC $15.91
- MGNX $0.99
- 52 Week High
- CPHC $22.93
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- CPHC 54.97
- MGNX 47.34
- Support Level
- CPHC $16.40
- MGNX $1.69
- Resistance Level
- CPHC $17.40
- MGNX $1.83
- Average True Range (ATR)
- CPHC 0.46
- MGNX 0.10
- MACD
- CPHC 0.09
- MGNX -0.00
- Stochastic Oscillator
- CPHC 69.54
- MGNX 15.00
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.